Brii Biosciences Limited BRIBF OTC

Other OTC • Healthcare • Biotechnology • CN • USD

SharesGrow Score

27/100

0/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Brii Biosciences Limited (BRIBF) .

本页证实的标准:

VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。

SharesGrow 综合评分： 25/100 其中 0/7 项标准通过。

SharesGrow 7-Criteria Score

27/100

SG Score

View full scorecard →

—

价值

N/A

No coverage

—

未來

N/A

No coverage

✗

过去

0/100

→ Income

健康

67/100

Debt-to-Equity & liquidity

→ Health

✗

护城河

0/100

→ Income

成长

58/100

→ Income

✗

收入

10/100

→ Income

估值概览 — BRIBF

估值倍数

P/E (TTM)0.0

前瞻 P/EN/A

PEG 比率N/A

前瞻 PEGN/A

P/B 比率0.00

P/S 比率7.50

EV/EBITDA0.0

每股数据

EPS (TTM)$-0.30

每股账面价值$0.00

每股营收$0.03

每股自由现金流$0.00

收益率与内在价值

盈利收益率N/A

股息收益率0.00%

EPS：实际 vs 预期

P/E Ratio & Earnings Yield

每股收益 (EPS) 历史

Year	EPS（稀释）	营收	净利润	净利润率
2019	$-0.73	$20.2M	$-516.84M	-2559.1%
2020	$-1.71	$82.22M	$-1.21B	-1467.2%
2021	$-9.38	$92.54M	$-4.12B	-4452.3%
2022	$-0.63	$51.63M	$-452.63M	-876.7%
2023	$-0.24	$617K	$-174.83M	-28335.3%
2024	$-0.70	$49.94M	$-508.16M	-1017.6%
2025	$-0.30	$18.12M	$-216.88M	-1196.6%